Biotechnology company Kallyope raised $21m in a funding round led by Polaris Partners founder Bill Gates to develop therapies based on the gut-brain axis. The backing was an extension to the firm’s series B funding round which had already raised $66m. The company developed a platform centred on analysis of the bi-directional communication between the gut and the brain and said it had expanded its research to a series of programmes aimed at studying disorders of the metabolic, central nervous and gastrointestinal systems.
Biotechnology company Kallyope raised $21m in a funding round led by Microsoft founder Bill Gates to develop therapies based on the gut-brain axis. The backing was an extension to the firm’s series B funding round which had already raised $66m. The company developed a platform centred on analysis of the bi-directional communication between the gut and the brain and said it had expanded its research to a series of programmes aimed at studying disorders of the metabolic, central nervous and gastrointestinal systems.